Surgery

You are here

Clinical Trials

The Department of Surgery doesn’t just excel in the operating room. Through our extensive and innovative research programs, we are also focused on the development of new techniques and therapies that promote better outcomes and improve the quality of life for patients following surgery. 

As part of that goal, the department’s surgeons are involved in groundbreaking clinical trials. In addition to their research value, clinical trials may also give patients access to new treatments that are not available anywhere else.

Learn more about our current clinical trials below or visit the Joint Clinical Trials Office at Weill Cornell Medicine and NewYork-Presbyterian.

This is a biomarker preselected, randomized, open-label, multicenter, phase II study in men with metastatic castration resistant prostate cancer (mCRPC).

Key Inclusion / Exclusion Criteria:
  • Men age 18 an older 
  • Documented progressive metastatic castration-resistant prostate cancer 
  • Adequate organ function 
  • Detailed eligibility reviewed when you contact the study team 

This randomized phase II/III trial studies how well paclitaxel, carboplatin, and metformin hydrochloride works and compares it to paclitaxel, carboplatin, and placebo in treating patients with endometrial cancer that is stage III, IV, or has come back.

The purpose of this study is to assess the effects of JNJ-64565111 compared with placebo after 26 weeks of treatment on the change in body weight from baseline and to assess the safety and tolerability of JNJ-64565111 in non-diabetic severely obese participants.

Key Inclusion / Exclusion Criteria:
  • Men and women age 18-70 
  • BMI ≥ 35 to ≤ 5 0 kg/m2 at the screening visit 
  • Stable weight (that is, change of < 5% within 12 weeks before screening based on medical history) 
  • No personal history of the following: Type 1 diabetes mellitus, T2DM, MI, unstable angina, revascularization procedure cardiac pacemaker or other electric implantable device, significant liver disease, pancreatitis, bariatric surgical procedure or a known clinically significant gastric emptying abnormality 
  • Detailed eligibility reviewed when you contact the study team. 

This clinical trial is for men and women with glioblastoma that has recurred or progressed. There is currently a need for more effective treatment methods for this disease. 

Key Inclusion / Exclusion Criteria:
  • Open to men and women above the age of 18 
  • Diagnosed with glioblastoma (GBM) at first recurrence or progression following primary therapy consisting of surgery (biopsy or resection) and chemoradiation 
  • Detailed eligibility will be reviewed when you contact the study team 

This clinical trial is for men age 18 and older with prostate cancer to check safety and tolerability of IMMU-132. 

Key Inclusion / Exclusion Criteria:
  • Open to men 18 years and older 
  • Pathologically confirmed prostate cancer and demonstrated disease progression 
  • Documented metastatic disease 
  • Patients who have previously received enzalutamide, abiraterone, or apalutamide
  • Detailed eligibility reviewed when you contact the study team

This clinical trial is for men and women with meningioma. Currently available treatments are not effective in treating patients with this disease. Therefore, there is a need to find treatments that work for patients with meningoioma.

Key Inclusion / Exclusion Criteria:
  • Men and women age 18 and older
  • Diagnosis of meningioma
  • Open to untreated and previously treated patients
  • Detailed eligibility reviewed when you contact the study team.

The purpose of this study is to examine brain cancer patients’ surgically removed tumors for certain molecular changes that may make them eligible to participate in the related treatment study. 

Key Inclusion / Exclusion Criteria:

   • Open to men and women age 18 and older 
   • Patients have not had a local MGMT testing 
   • Newly diagnosed Grade IV intracranial gliobastoma or gliosarcoma 
   • Patients must have completed standard radiotherapy and TMZ therapy 
   • No other therapy has been done (Neoadjuvant or adjuvant) which includes chemotherapy, biologics, immunotherapy, and radiation therapy. 
   • Detailed eligibility reviewed when you contact the study team.

Standard treatment for advanced germ cell tumors includes three chemotherapy drugs called BEP (Bleomycin, Etoposide, and cisPlatin). BEP is given with a drug called pegfilgrastim or filgrastim which makes white blood cells grow. These drugs are given over the course of 3 weeks.

Key Inclusion / Exclusion Criteria:
  • Age 11 years and 45 years on the date of randomization
  • Histologically or cytologically confirmed germ cell tumour (non-seminoma or seminoma); or exceptionally raised tumour markers (AFP 1000ng/mL and/or HCG 5000 IU/L) without histologic or cytologic confirmation in the rare case where pattern of metastases consistent with GCT, high tumour burden, and a need to start therapy urgently 
  • Primary arising in testis, ovary, retro-peritoneum, or mediastinum 
  • Metastatic disease or non-testicular primary 
  • Study treatment both planned and able to start within 14 days of randomization
  • Willing and able to comply with all study requirements, including treatment, timing and nature of required assessments 
  • Able to provide signed, written informed consent 
  • Detailed eligibility reviewed when you contact the study team. 

This clinical trial is for men and women age ≥ 18 years old who have been diagnosed with advanced rectum cancer.

Key Inclusion / Exclusion Criteria:
  • This trial is open to men and women ages 18 and up at the time of informed consent who have been diagnosed with invasive primary rectal cancer. 
  • No prior pelvic radiotherapy, chemotherapy, immunotherapy or other anti-cancer treatment for rectal cancer is acceptable. 

This clinical trial is for men and women age ≥ 18 years old who have been diagnosed with advanced rectum cancer.

Key Inclusion / Exclusion Criteria:

   • Open to men and women, Age ≥18 years at the time of informed consent who have been diagnosed with invasive primary rectal cancer
   • No prior pelvic radiotherapy, chemotherapy, immunotherapy or other anti-cancer treatment for rectal cancer
   • Ability to read and provide signed informed consent. Patients may not be consented by a durable power of attorney.
   • Ability and willingness to comply with scheduled study visits, treatment plans, laboratory tests and other study related procedures 

Additional eligibility criteria reviewed when you contact the study team. 

Find a Physician

Surgical Services
Weill Cornell Medicine Surgery

Visit our Surgery YouTube channel to view our video library.